Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

SDĚLENÍ

Ministerstva zahraničních xxxx,

xxxxxx xx mění x xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, xx xxx 1. října 2023 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx.

X xxxxx zněním Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx České republiky x prezident republiky xxxxxxxx listinu x xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku vstoupilo x xxxxxxxx dne 18. xxxxxx 2024 x nahradilo Xxxxxxx X xxx rok 2023, platnou xx 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx pro Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X pro rok 2024 x xxxx xxxxxxx do xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. XXXx. Xxxxxx, Xx.X., LL.M., x. x.

xxxxxx ředitel xxxxx právní x xxxxxxxxxx
&xxxx;

Xxxxxxx č. 1

Xxxxxxx xxxxxxxxxxx xxxxxxx do xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx je povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Světového antidopingového xxxxxxxx.

Xxxxxx je xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou agenturou (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx text Xxxxxxx xxxxxxxxxx xxxxx x xxxxx bude xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X případě jakýchkoliv xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění x xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx xxxxx používané x xxxxx Xxxxxxx xxxxxxxxxx látek a xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX pro daný xxxxx xxxxxxxxxxx xxxx xxxxxx, je xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 xxxxx) x xxx předcházející Xxxxxxx, které se xx Sportovec xxxxxxxxx, xx xx konce Xxxxxxx x xxxxxxx xxxxxx Vzorku.

Zakázané xxxxx

Xx xxxxxxx, xx xxxx xxxxx xxxx metoda xx xxxxxxxx Xxx xxxxxxx i Xxxx xxxxxx, xxx je xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Nespecifické

Podle xxxxxx 4.2.2 Xxxxxxxxx antidopingového Xxxxxx „xxx účely xxxxxxxx xxxxxx 10 xxxxx všechny Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx těch xxxxxxxxxx x Xxxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx metodou, pokud xxxx v Xxxxxxx xxxxxxxxx označena jako Xxxxxxxxxx metoda.“ Xxxxx xxxxxxxxx x článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx uvedené x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx považovány xx xxxx xxxxxxxx xxxx méně xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx xxxx metody. Xxx xxxxx o xxxxx a xxxxxx, xxxxx Sportovec pravděpodobně xxxx xxxx použil x xxxxxx xxxxx xxx xx xxxxxxxx xxxxxxxxxxx výkonu.“

Návykové xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx látky xxxxxxxxxx jako látky, xxxxx xxxx xxxx xxxxxx označeny x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx ve xxxxxxxxxxx xxxx rámec sportu. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx nevztahuje xxxxx x následujících xxxxxx Seznamu a xxxxx xxxx x xxxxxxxx xxxx xxxxxxxxx xxxxxx vládním xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pro xxxxxxx použití x xxxx (např. léčiva x předklinickém xxxx xxxxxxxxx vývoji xxxx xxxxxxx xxxxx byl xxxxxxx, syntetické xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, xxxx xxxx BPC-157, 2,4-xxxxxxxxxxxx (XXX) a aktivátory xxxxxxxxx (xxxx. Reldesemtiv x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx jsou xxxxxxxx.

X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion)		•	furazabol (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol)
•	1-androsteron (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on)		•	mesterolon
•	4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)
•	4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)		•	metenolon
•	5-androstenedion (androst-5-en-3,17-dion)		•	metandriol
•	7ɑ-hydroxy-DHEA		•	metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on)		•	nandrolon (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (androsta-1,4-dien-3,17-dion)		•	oxandrolon
•	calusteron		•	oxymesteron
•	klostebol		•	oxymetolon
•	danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on)		•	prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)		•	testosteron
•	epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-hydroxyestr-4,9,11-trien-3-on)
•	fluoxymesteron		•	trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx včetně:

Clenbuterol, osilodrostat, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], xxxxxxx x xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

XXXXXXXX XXXXX (PŘI SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx látky x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X XXXXX OVLIVŇUJÍCÍ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx sloučeniny, např. XXXX-530, xxxxxxxxxxx.

X2.1.2 Aktivační xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); roxadustat (FG-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), např. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Agonisté xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo XXX; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx stimulující testosteron x mužů, xxxx xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (LH),

• xxxxxx xxxxxxxxxx gonadotropin (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x xxxx agonistické xxxxxxx.

X2.2.2 Kortikotropiny x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxx x fragmenty, mimo xxxx včetně:

• analogy xxxxxxxxx xxxxxxx, např. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, xxxx. XXX-9604 x xXX 176–191.

S2.2.4 Xxxxxxx uvolňující xxxxxxx xxxxxx, xxxx xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx hormon (GHRH) x xxxx analogy, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx a tesamorelin,

• xxxxxxxxxxx růstového xxxxxxx (XXX) x jejich xxxxxxxx [xxxx. anamorelin, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx a tabimorelin],

• xxxxxxx xxxxxxxxxx XX (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), GHRP-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx růstové faktory (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)

• růstový xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx analogy

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)

• thymosin-β4 x xxxx xxxxxxxx, xxxx. XX-500

• vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX)

x xxxxx xxxxxxx faktory xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx svalech, xxxxxxxx nebo xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx typy xxxxxxxxx xxxxxx.

X3 XXXX-2 AGONISTÉ

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx x xxxx třídě jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx beta-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx salbutamol: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 hodin xx xxxxxxxxx xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx xx 24 hodin.

POZNÁMKA

Přítomnost xxxxxxxxxxx x xxxx v xxxxxxxx xxxxxx xxx 1000 ng/ml nebo xxxxxxxxxxx x množství xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx xx výše xxxxxxx xxxxxxxxx dávky.

S4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx X4.1 a X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx do xxxx S4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx jsou xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)		•	formestan
•	4-androsten-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX A XXXXXXXXXX XXXXXXXXXX ESTROGENOVÝCH RECEPTORŮ (XXXXX)]

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx včetně:

•	protilátky xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, např.:
•	konkurenty xxxxxxxxx xxxxxxxx IIB, xxxx.:			- xxxxx snižující xxxx xxxxxx xxxxxxx xxxxxxxxxx
	- xxxxxxx receptory xxxxxxxx (xxxx. XXX-031)			- proteiny xxxxxx myostatin (xxxx. xxxxxxxxxxx, xxxxxxxxx myostatinu)
•	protilátky xxxxx receptoru xxxxxxxx XXX (xxxx. bimagrumab)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, stamulumab)

S4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), např. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516) x agonisté Xxx-xxxɑ , xxxx. XX9009, XX9011

X4.4.2 insuliny x xxxxxxxx insulinů

S4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 DIURETIKA X XXXXXXXXX LÁTKY

ZAKÁZANÉ STÁLE (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx zakázané xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx x xxxxxxxxx látky, xxxxxx xxxxx optických xxxxxxx, xxxx. x- a x-, jsou xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx např.:

acetazolamid; xxxxxxxx; xxxxxxxxx; kanrenon; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, xxxx. bendroflumethiazid, xxxxxxxxxxxxx x hydrochlorothiazid; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. konivaptan, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, např.:

albumin, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx látky s xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx oftalmologické xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, brinzolamid);

• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx anestezii.

POZNÁMKA

Nález xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx: u formoterolu, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Vzorku Sportovce xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx (kromě lokálního xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx felypresinu x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx za Pozitivní xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx xxxx xxxxx navíc k xx, která xxx xxxx udělena na xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxxx x xxxx xxxxx jsou Xxxxxxxxxxxx x výjimkou xxxxx v X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX X XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je následující:

M1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, allogenní (homologní) xxxx heterologní xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx x výjimkou xxxxxxxx xxxxxx nebo xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx nebo xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; efaproxiral (XXX13); xxxxxxxxx a modifikované xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx náhražky na xxxx hemoglobinu a xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx intravaskulární manipulace x krví xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx nebo xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX MANIPULACE

Zakázané xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx o xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole.

Mimo jiné xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, např. xxxxxxxx xxxxxxx ke Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx vyšetření.

M3. GENOVÝ X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:

M3.1. Xxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx, které xxxxx změnit sekvence xxxxxx x/xxxx exprese xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx xxxx xxxxxxxx xxxxxxxxxxx úprav xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx přenosů xxxx.

X3.2. Použití xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky x xxxxxxxx xxxxx xxxxxxxxx v X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a x-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

•	adrafinil		•	fonturacetam [4-fenylpiracetam (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx není xxxxxxxx xxxxxx v xxxxx oddíle, je Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx a xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx x xxxx xxxxxxx, např. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (adrenalin)4)		•	metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• klonidin;

• xxxxxxxx xxxxxxxxxxx v xxxxxxx xxxxxx xxxxxxx, xxxxxxx, očního nebo xxxxxx xxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xylometazolin) x stimulancia xxxxxxxx xx Monitorovacího programu 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x této xxxxx: diamorfin (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx všech optických xxxxxxx, např. d- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx a xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 XXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny zakázané xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx. Návykové látky x této xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x syntetické xxxxxxxxxxx xxxx xxxxxxxx, xxxx.

• x konopí (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx a xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx v xxxx třídě jsou Xxxxxxxxxx látky.

Všechny xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx cestou.

Mimo jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx acetonid
•	kortizon		•	hydrokortizon
•	deflazakort		•	metylprednisolon

POZNÁMKA

• Jiné xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x topického: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, intranazálního, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx zakázány, xxxxx se používají x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx x xxx xx xx označeno xxxxxxxx (*) i Xxxx soutěž.

• lukostřelba (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx skoky / X-xxxxx x xxxxxxxxx X-xxxxx / xxx xxx

• xxxxxxxxxxxx xxxxx (FIA)

• podvodní xxxxxx (XXXX)* v xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx harpunou x xxxxxxx na xxxx

• xxxxxxxx (xxxxxxx disciplíny) (XXXX)

• šipky (XXX)

• xxxx (XXX)

• minigolf (XXX)

• střelba (XXXX, XXX)*

* zakázané xxxx Xxxx xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx č. 2

Znění xxxxxxxxxxx smlouvy v xxxxxxxxx xxxxxx
&xxxx;

¹⁾ katin (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx x moči xxxxx xxx 5 xxxxxxxxxx x 1 xx.

²⁾ xxxxxxxxxxxxx: zakázaný xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 150 xxxxxxxxxx x 1 xx.

³⁾ xxxxxxx x xxxxxxxxxxxx: zakázány xxx koncentraci x xxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx.

⁴⁾ epinefrin (xxxxxxxxx): xxxx zakázáno xxxxxxx xxxxxxxx, např. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

⁵⁾ bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol x xxxxxxxx: xxxx xxxxx xxxx zahrnuté do Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx č. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, xxxxx xx xxxx netýká xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu